2021
Infiltration of Gamma-delta T cells into Glioblastoma Tumor
JURÁŇ, Vilém; Barbora KOHLOVÁ; Martin PISKÁČEK; Vít ZMÁTLO; Leonard JAKUBÁČ et al.Základní údaje
Originální název
Infiltration of Gamma-delta T cells into Glioblastoma Tumor
Autoři
JURÁŇ, Vilém; Barbora KOHLOVÁ; Martin PISKÁČEK; Vít ZMÁTLO; Leonard JAKUBÁČ; Veronika MOTÚZOVÁ; Marie TOMANDLOVÁ; Marek SOVA; Tomáš KAZDA; Václav VYBÍHAL; Pavel FADRUS a Andrea KNIGHT
Vydání
WFNOS 2022 - the World Federation of Neuro-Oncology Societies (WFNOS), Seoul, South Korea, 2021
Další údaje
Jazyk
angličtina
Typ výsledku
Konferenční abstrakt
Utajení
není předmětem státního či obchodního tajemství
Označené pro přenos do RIV
Ne
Organizační jednotka
Lékařská fakulta
Změněno: 26. 1. 2022 12:40, Mgr. Tereza Miškechová
Anotace
V originále
Gamma-delta (γδ) T cells are innate immunity effector lymphocytes with known prominent anti-tumor reactivity against aggressive glioblastoma (GBM). However, therapeutic approaches have had limited success due to the protective blood-brain-barrier and the immunosuppressive GBM tumor microenvironment. In this study, we determined Vδ1 a Vδ2 γδ T cell populations in peripheral blood and paired tumor tissue samples in patients (n=40) following the resection and throughtout the therapy follow-up. Tumor samples were processed using enzymatic kits and gentleMACSTM Dissociator (Miltenyi Biotec Inc.) and tumor-infiltrating γδ T lymphocytes (TILs) were analyzed by flow cytometry. We found infiltration of both intratumoral CD3+ γδ T cell subsets in 68% tumor samples. We detected Vδ1 γδ T cells in the range 0-0.8% (median 0.26%). Majority of GBM patients presented the Vδ2 subset among TILs in the range 0-13.8% (median 1.5%). Functional studies showed prominent cytotoxicity of magnetically sorted Vδ1 a Vδ2 γδ T cells against GBM cell lines and more importantly against primary tumors. Detailed phenotypic profiling and single-cell sequencing of Vδ2 γδ T cells is currently underway. Next, we identified the EphA2 receptor as one of the targets for tumor-reactive Vδ1 γδ T cells. Specifically, we found that blocking of EphA2 expression resulted in significant inhibition of GBM killing mediated by Vδ1 γδ T cells. Furthermore, multiplex analysis of soluble proteins in patients‘ plasma samples determined by Luminex® 200™ has identified significantly elevated levels of stress ligand MICA and check-point inhibitor ligands PD-L1 (B7-H1, CD274) and B7-H3 (CD276). The patient’s clinical course and therapeutic protocols will be discussed.
Návaznosti
| NV19-05-00410, projekt VaV |
|